trial

Sodium Nitroprusside in Early Course Schizophrenia

NCTId NCT04986072
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 1 (actual)
Sponsored by Beth Israel Deaconess Medical Center
Primary completion 2024-06-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
1 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2022-03-14
Primary completion
2024-06-01
Eligibility
ALL · 18 Years · 40 Years

Interventions & indications

Drugs
Sodium nitroprusside5% Dextrose solution

Sponsors

Beth Israel Deaconess Medical CenterLead Sponsor

Investigators

1
Paulo Lizano, MD, PhDPrincipal Investigator

Sites

1 total
Boston, United States

Linked catalysts

1
Sodium Nitroprusside in Early Course Schizophrenia — primary completion2024-06-01

Facts & assertions

4 sourced
Enrollment
1
Phase
PHASE2
Primary Completion Date
2024-06-01
Status
TERMINATED
relationships
The graph out of here
drug
Sodium nitroprusside
drug
5% Dextrose solution
drug
lead_sponsor
Beth Israel Deaconess Medical Center
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Paulo Lizano, MD, PhD
person